Ariel Rubashkin

Ariel Rubashkin has a diverse work experience in the medical, biotech, and finance industries. Ariel is currently the Chief Financial Officer at MeMed, a leading med tech and bio-convergence company focused on developing innovative diagnostic testing methods for infectious diseases and inflammatory disorders. Prior to MeMed, Ariel served as a Board Member at EndyMed Medical and Vice President of Business Economics at DarioHealth Corp. Ariel also held executive positions at AllMeD Solutions, Allevetix Medical Ltd, TruLeaf Medical, Allium Ltd, Syneron Candela, and Rivulis Irrigation. Ariel started their career as a Senior Audit Associate at EY Israel.

Ariel Rubashkin's education history includes a Bachelor's degree in Accounting and Finance from the University of Haifa, obtained between 2000 and 2003. Ariel also pursued a Master's degree in Business Administration (M.B.A.) from Tel Aviv University from 2008 to 2009. In 2020, they attended the Technion - Israel Institute of Technology for a course on Directors and Chief Executive Officers. Additionally, Ariel has obtained various certifications, including Investor Relations and Mentor certifications from the IIRF-Israeli Investor Relations Forum and the Institute of Certified Public Accountants in Israel, respectively. Ariel is also certified as a Certified Public Accountant (CPA) by the Institute of Certified Public Accountants in Israel.